Senior Director, Medical Affairs Strategy

Sumitomo Pharma Co., Ltd. is a global pharmaceutical company based in Japan with key operations in the U.S. (Sumitomo Pharma America, Inc.), Canada (Sumitomo Pharma Canada, Inc.) and Europe (Sumitomo Pharma Switzerland GmbH) focused on addressing patient needs in oncology, urology, women's health, rare diseases, psychiatry & neurology, and cell & gene therapies. With several marketed products in the U.S., Canada, and Europe, a diverse pipeline of early- to late-stage assets, and in-house advanced technology capabilities, we aim to accelerate discovery, research, and development to bring novel therapies to patients sooner. For more information on SMPA, visit our website https://www.us.sumitomo-pharma.com or follow us on LinkedIn.

Job Overview

The Sr. Director, Medical Strategy (Rare Disease) will be a key member of the Medical Affairs team reporting to the Executive Director, Medical Affairs Strategy.   The job is responsible for strategic direction and management for RETHYMIC (allogeneic processed thymus tissue–agdc), indicated for immune reconstitution in pediatric patients with congenital athymia.   RETHYMIC is the first and only FDA-approved tissue-based treatment for congenital athymia, engineered to help children develop an immune system sufficient to fight infections.

The role will provide set Medical Strategy for both internal company programs and external facing HCP and Payer interactions. The Sr. Director of Medical Affairs develops and maintains professional relationships with key physicians and other health care providers to conduct external scientific information exchange, gain clinical and scientific insights, and help identify unmet medical needs.  The job requires conducting peer to peer conversations regarding clinical immunology and give presentations on congenital athymia, an ultra-rare indication, working across multiple specialist types in a complex care setting.   

This job will effectively lead and communicate with cross-functional team members to share and gain insights that help SMPA meet the unmet medical needs of this ultra-rare disease community.  The role will also collaborate closely with Commercial leadership and advance patient advocacy efforts to ensure that Medical Affairs activities align with patient focused programs.

Job Duties and Responsibilities

• Develops and aligns medical affairs strategic plans with brand strategic imperatives that support impactful insights, data generation, and data communication plans to support education and awareness to HCP stakeholders and healthcare payers.
• Leads the creation and execution of evidence generation plans to enhance the value of RETHYMIC in a real-world setting, including continuation of product registry and Natural History Study. 
• Collaborates with Scientific Communication in the development and implementation of detailed scientific Publication Plans, Medical Advisory Boards, and Patient Advisory Boards upon review and approval of Legal and Compliance process.
• Critically evaluates information gained from published studies, and HCP interactions to develop key insights that deepen our understanding of the market’s needs and opinions of external stakeholders and therefore contribute to enhancement of scientific messages, plans, and strategy.
• Develops and sustains relationships with key HCPs to support compliant exchange of scientific and medical information including Advisory Boards and presentations at national and international meetings.
• Represents the Medical Affairs department on the RETHYMIC lifecycle team to provide medical affairs input to Clinical Research and Clinical Operation’s needs.
• Assesses and approves long-term Medical Education programming or Medical Affairs Sponsorships with Advocacy and Medical Education Groups
• Provides input into the development of Areas of Interest supporting research and presents research concepts to internal Review Committee for Investigator Initiated Study (IIS) concepts and research protocols.
• Leads internal and external training on congenital athymia disease state and label education to ensure consistent information about RETHYMIC.
• Engages with appropriate Market Access stakeholders to understand the state of healthcare polic